BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Sanofi Pharma Bristol-Myers Squibb SNC submitted on 6 September 2006 an 
application for Marketing Authorisation to the European Medicines Agency (EMEA) for Irbesartan 
Hydrochlorothiazide Winthrop, through the centralised procedure according to Regulation (EC) No 
726/2004. 
The legal basis for this application refers to Article 10c of Directive 2001/83/EC, as amended – 
relating to informed consent from the marketing authorisation holder, Sanofi Pharma Bristol-Myers 
Squibb SNC, for the authorised medicinal product COAPROVEL (EU/1/98/086/001-0022). 
Scientific Advice: 
The applicant did not seek scientific advice at the CHMP. 
Licensing status: 
The initial product, COAPROVEL, has been given a Community Marketing Authorisation on 15 
October 1998.  
The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: 
Rapporteur: Concepción Prieto Yerro 
Co-Rapporteur: Pirjo Laitinen-Parkkonen 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 6 September 2006. 
The procedure started on 27 September 2006  
The Rapporteur's first Assessment Report was circulated to all CHMP members on 16 October 
2006. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 13 
October 2006. 
The  Rapporteur  circulated  an  updated  Assessment  Report  to  all  CHMP  members  on  13 
November 2006.  
During  the  meeting  on  13-16  November  2006,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting  a  Marketing  Authorisation  to  Irbesartan  Hydrochlorothiazide  Winthrop  on  16 
November 2006. The applicant provided the letter of undertaking on the follow-up measures to 
be fulfilled post-authorisation on 14 November 2006. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 19 January 2007. 
©EMEA 2007 
 
 
 
 
 
 
 
 
 
 
 
